Clinical trials: Non-Tuberculous Mycobacteria Pulmonary Disease
Tuberculosis, Pulmonary
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
This study is a clinical trial conducted to determine whether the sitafloxacin-containing three-month regimens are as effective as the standard six-month regimen and the four-month rifapentine and moxifloxacin regimen…
- Trial name
- NCT05454345
- Testing
- Sitafloxacin, SMZ/TMP, Rifampin
- Volunteers
- 620 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Tuberculosis, Pulmonary
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
The purpose of the study is to evaluate the safety and efficacy of two shortened regimens for newly diagnosed smear positive drug susceptible pulmonary tuberculosis in comparison to World Health Organization recommended standard…
- Trial name
- NCT02901288
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- 35 sites in China
- Volunteers
- 3,900 people
- Sponsor
- Beijing Chest Hospital
Cystic Fibrosis, Nontuberculous Mycobacterium Infection
Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic Fibrosis
Sources of NTM infection and modes of transmission among CF patients are poorly understood. Healthcare-associated transmission of NTM among CF patients has been suspected and is of growing concern for CF Centers.
- Trial name
- HALTNTM (NCT04024423)
- Testing
- Epidemiologic investigation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Jewish Health
Cystic Fibrosis, Atypical Mycobacterium Infection
Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients
OBJECTIVES: I. Determine the prevalence of nontuberculous mycobacteria in sputum cultures from patients with cystic fibrosis. II. Compare the clinical course of patients with negative versus positive cultures.
- Trial name
- NCT00004296
- Volunteers
- 1,000 people
- Sponsor
- National Center for Research Resources (NCRR)
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
To evaluate the pharmacokinetics (PK) of SPR719, the active moiety, generated from the orally (po) administered SPR720 prodrug in a patient population with nontuberculous mycobacteria pulmonary disease (NTM-PD)
- Trial name
- NCT04553406
- Testing
- SPR720, Open-label Standard of Care
- Where
- 9 sites in United States
- Volunteers
- 2 people
- Sponsor
- Spero Therapeutics
Cystic Fibrosis
PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis
Isolation of nontuberculous mycobacteria (NTM) from the sputum of individuals with CF is an increasingly common finding, and the lack of an evidenced-based approach to the diagnosis of NTM disease has been identified as one of…
- Trial name
- PREDICT (NCT02073409)
- Where
- 19 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Jewish Health
Pulmonary Tuberculosis
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of bedaquiline plus PA-824 plus linezolid after 6 months of treatment (option for 9 months for participants who remain culture…
- Trial name
- NCT02333799
- Testing
- Bedaquiline, PA-824, Linezolid
- Where
- 3 sites in South Africa
- Volunteers
- 109 people
- Sponsor
- Global Alliance for TB Drug Development
MAC Lung Disease, Treatment Refractory MAC Lung Disease
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease.
- Trial name
- NCT05327803
- Testing
- Epetraborole
- Where
- 91 sites in United States, Australia and 2 more
- Volunteers
- 177 people
- Sponsor
- AN2 Therapeutics, Inc
Nontuberculous Mycobacterial Pulmonary Infection, Outbreak Investigation
Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)
The goal of this observational study is to support U.S. healthcare centers in determining if they may have an NTM outbreak among patients receiving care at the healthcare center.
- Conditions
- Nontuberculous Mycobacterial Pulmonary Infection, Outbreak Investigation, Healthcare Associated Infection, Mycobacterium Infections
- Trial name
- TrANsMIt (NCT06155747)
- Testing
- Epidemiologic investigation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Mediastinal Lymphadenopathy, Hilar Lymphadenopathy
Endobronchial Ultrasound Needle Aspiration With and Without Suction
The main purpose of the present study is to compare the diagnostic yield of different aspiration techniques in Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) in the diagnosis of hilar/mediastinal adenopathy
- Conditions
- Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma, Lung Neoplasms
- Trial name
- NCT05110950
- Testing
- No suction EBUS-TBNA, Passive suction through dedicated EBUS-TBNA syringe, Manual applied suction EBUS-TBNA through a pistol-grip syringe holder
- Where
- Italy
- Volunteers
- 306 people
- Sponsor
- Università Politecnica delle Marche
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
NTM therapy consists of a multi-drug macrolide based regimen for 18-24 months. Treated patients frequently experience debilitating side effects, and many patients delay the start of antibiotic treatment due to these risks.
- Trial name
- MAC2v3 (NCT03672630)
- Testing
- Azithromycin, Ethambutol, Rifampin
- Where
- 26 sites in United States, Canada
- Volunteers
- 474 people
- Sponsor
- Kevin Winthrop
Cystic Fibrosis, Bronchiectasis Adult
Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.
- Conditions
- Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
- Trial name
- NCT04884308
- Testing
- BCG TICE Vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Respiratory Tract Infections, Corona Virus Infection
Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections
Non tuberculous mycobacteria (NTM), Burkholdria spp, Aspergillus in the lung are almost impossible to eradicate with conventional antibiotics. In addition COVID-19 has know current treatment.
- Trial name
- NCT03331445
- Testing
- Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Chris Miller
Non - Tuberculosis Mycobacteria Lung Disease
NTM-LD Treatment Based on GenSeizer Characteristic Gene Capture Strategy
Treatment of non - tuberculosis mycobacteria lung disease is challenging. The current treatment used is from 2007 American Thoracic Society guidelines recommended antibiotic combination therapy, which is lack of validation of…
- Trial name
- NCT03224065
- Testing
- Genotype detected through GenSeizer high-throughput gene capture technology
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Nontuberculous Mycobacteria, Bronchiectasis
Evaluation Of The Lung Microbiome In NTM Bronchiectasis
A biomarker cohort study design is proposed to study whether specific airway microbiota alterations are associated with pulmonary Non-tuberculous mycobacteria (NTM) disease.
- Trial name
- NCT02779478
- Testing
- Bronchoscopy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- NYU Langone Health
Active Tuberculosis, Latent Tuberculosis Infection
Performance Evaluation of the VIDAS TB-IGRA Assay.
This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection.
- Conditions
- Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
- Trial name
- NCT04048018
- Testing
- Blood draw and IGRA test
- Where
- 24 sites in United States, Brazil and 7 more
- Volunteers
- 2,401 people, healthy volunteers welcome
- Sponsor
- BioMérieux
Tuberculosis
Improving the Outcomes of Children With Tuberculosis Through Innovative Diagnostics and Treatment Monitoring
This study aims at identifying and evaluating novel diagnostic methods for children evaluated for respiratory tuberculosis. The investigators will use alternative samples like stool, urine, and masks to diagnose children with…
- Trial name
- RoGer Pedi (NCT06815588)
- Where
- Romania
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Research Center Borstel
Mycobacterium Abscessus Infection
Epetraborole in Patients With Mycobacterium Abscessus Lung Disease
This double-blind, randomized, placebo-controlled, parallel-group, multicenter, prospective, investigator-initiated trial will evaluate epetraborole (EBO) monotherapy in the treatment of adults with Mycobacterium abscessus…
- Trial name
- REBOUND (NCT07301320)
- Testing
- Epetraborole
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Kevin Winthrop
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in…
- Conditions
- Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections
- Trial name
- POSTSTAMP (NCT06262282)
- Testing
- mycobacteriophage
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health
Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis Lung
Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis
In this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of M.
- Trial name
- BioMol-MA (NCT06413459)
- Testing
- Luminex; scRNAsec
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Ospedale San Raffaele